This review has summarized data on the salutary effects of SGLT2 inhibition unrelated to glucose metabolism, including changes in sodium balance, sodium sensitivity, and direct sodium effects, on the heart and nonosmotic sodium stores, and hypothesized that these may partly contribute to improved HF outcomes. This evidence concerns the gene SLC5A2 and hydrops fetalis.